

Announcement No. 2/2017
23 February 2017Coloplast A/S
Holtedam 1
3050 Humlebæk
Denmark
Tel: +45 4911 1111
www.coloplast.com
CVR-nr. 69749917**Coloplast initiates the second part of the DKK 1bn share buy-back programme**

Coloplast A/S is initiating the second part of the share buy-back programme totalling up to DKK 1bn, cf. announcement no. 4/2016 of 16 February 2016. The second part of the programme of DKK 500 million will commence on 27 February 2017 and is expected to end by 28 August 2017. The first part of the programme, amounting to DKK 500 million, was executed in the 2015/16 fiscal year.

The buy-back programme is being launched within the authority granted by the shareholders at the Annual General Meeting on 5 December 2016, for the repurchase of up to 10% of the company's share capital.

The buy-back programme will be structured in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Regulation 2016/1052, also referred to as the "Safe Harbour" rules, which ensure that the company is protected against violation of insider legislation in connection with the buyback programme.

The company has entered into a contract with UBS, in which UBS agrees to act as manager of the second part of the buy-back programme for DKK 500 million, and purchase shares on behalf of Coloplast A/S. UBS has also agreed under the contract to make its trading decisions in relation to the shares in the company independently of, and without influence by, the company.

Coloplast is entitled to discontinue the repurchase during the life of the buy-back programme. If the company decides to discontinue the repurchase, such a decision will be disclosed to the public by announcement to Nasdaq Copenhagen. Once effective, UBS will no longer be entitled to purchase shares in Coloplast A/S on behalf of the company.

The second part of the buy-back programme is subject to the following terms:

- The programme will commence on 27 February 2017 and is expected to end by 28 August 2017.
- The volume of trading in own shares will be limited to a maximum total market value of DKK 500 million. Based on the current share price the approximate number of shares expected to be acquired under the buy-back programme is 1,016,000 B-shares, equivalent to 0.5% of the share capital of Coloplast A/S.
- The maximum number of shares to be purchased in the company per daily market session will be the equivalent to 25% of the average volume of shares in the company traded on Nasdaq Copenhagen during the preceding 20 business days.
- During the life of the buy-back programme no shares will be purchased at a price exceeding the higher of the following two prices:
 - i) the price of the last independent trade and
 - ii) the highest current independent bid on Nasdaq Copenhagen.

Details of transactions executed under the buy-back programme will be publicly disclosed on www.coloplast.com no later than the end of the seventh daily market session.

Prior to the launch of the share buy-back programme Coloplast's holds 3,721,929 treasury shares, equal to 1.7% of the company's share capital.

Anders Lonning-Skovgaard
CFO

For further information, please contact

Investors and analysts

Ellen Bjurgert
Director, Investor Relations
Tel. +45 4911 3376
E-mail: dkebj@coloplast.com

Press and the media

Maria Lindeberg
Sr. Media Relations Manager, Corporate Communications
Tel. +45 4911 3095
E-mail: dkmalg@coloplast.com

This announcement is available in a Danish and an English-language version. In the event of any discrepancies, the Danish version shall prevail.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2017-02 All rights reserved. Coloplast A/S, 3050 Humlebæk, Denmark.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.

Our business includes Ostomy Care, Urology Care, Contenance Care and Wound and Skin Care. We operate globally and employ around 11,000 people.